MiNK Therapeutics Reports Q3 2026 Financial Results and Clinical Updates
MiNK Therapeutics (INKT) reported its third quarter 2026 financial results, highlighted by the company's first pre-commercial revenue from agenT-797 via a named patient program. Despite a net loss of $2.6 million ($0.50 per share), the company saw an improvement in net loss compared to the prior year and a significant 44% reduction in G&A expenses due to lower professional fees and stock compensation. The company is heavily focused on its clinical pipeline, specifically targeting ARDS with agenT-797, where early observations suggest survival rates of 70%-75% compared to historical mortality benchmarks. While management noted a delay in the Phase I study for GvHD prevention moving to the second half of the year, they remain focused on upcoming data readouts for colorectal cancer and ARDS expected in 2027.
Tickers: $INKT
Topics: clinical trials earnings report net loss R&D expenses revenue announcement